We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

101 hedge funds and large institutions have $228M invested in Endocyte, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 33 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 33

5% more capital invested

Capital invested by funds: $216M → $228M (+$11.7M)

9% less funds holding

Funds holding: 111 → 101 (-10)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

80% less call options, than puts

Call options by funds: $935K | Put options by funds: $4.79M

Holders
101
Holders Change
-10
Holders Change %
-9.01%
% of All Funds
3.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
40
Reduced
33
Closed
25
Calls
$935K
Puts
$4.79M
Net Calls
-$3.85M
Net Calls Change
-$4.59M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$20.1M
2
PA
Pinnacle Associates
New York
+$9.83M
3
RIM
RS Investment Management
California
+$7.59M
4
PA
Perceptive Advisors
New York
+$5.53M
5
BFA
BlackRock Fund Advisors
California
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.69M
2
MG
Meditor Group
Bermuda
-$4.4M
3
American Century Companies
American Century Companies
Missouri
-$2.38M
4
BIM
Bogle Investment Management
Massachusetts
-$2.04M
5
FCM
Farallon Capital Management
California
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSG
126
Summit Securities Group
New York
– -$11K -800 Closed
2 3 4 5
6

ECYT Hedge Fund Activity: Q3 2013 in Review

101 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2013, worth a combined $228M — up 5.4% from $216M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of ECYT and 15 opened new positions — a net loss of 10 holders — while 33 trimmed existing stakes and 40 added.

The largest buyer was Fidelity Investments, adding an estimated $20.1M. The largest seller was OrbiMed, exiting entirely with an estimated $8.69M sold.

  • 101 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2013, down from 111 in Q2 2013.
  • Funds reported $228M of Endocyte, Inc. Common Stock stock for Q3 2013, up 5.4% quarter-over-quarter.
  • 15 funds opened new Endocyte, Inc. Common Stock positions in Q3 2013 and 25 closed out, a net change of -10 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q3 2013 was Fidelity Investments, an estimated $20.1M added.
  • The largest Endocyte, Inc. Common Stock seller in Q3 2013 was OrbiMed, an estimated $8.69M sold.

Based on aggregated 13F filings for Q3 2013.